An interventional study of Immediate Antibiotic Prescribing Group Instructions and Safety Net Antibiotic Prescribing (SNAP) Group Instructions in Community Acquired Pneumonia (CAP) and Community Acquired Pneumonia, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. Recruiting at 9 sites in United States. Open to participants aged 12 Months to 71 Months. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Ann & Robert H Lurie Children's Hospital of Chicago · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Community-Acquired Pneumonia with a site in United States — 9 open to participants now, 12 under way, 3 of them phase 3. Community-Acquired Pneumonia · United States.
Among the 52 studies in Community-Acquired Pneumonia with a site in United States, this one is the 6th largest by planned enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2025, is one of 12 with no phase, reaches primary completion later than 10 of the 11 other live ones, and was the 48th registered.
325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.
Browse Community-Acquired Pneumonia studies →9 of the 52 studies in Community-Acquired Pneumonia with a site in United States are open now. Recruiting first, the newest first:
Op-T LLC · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Medical College of Wisconsin · Sites in United States
Ages 3 mo–18 yrs
University of Manitoba · Sites in United States, Brazil, Canada and 1 more country
Ages 18+
Biotest · Sites in United States, Argentina, Australia and 15 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.
This study: 12 Months to 71 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 10 · Phase 4 7
First in 2001; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 246 across 196 interventional studies indexed under Community-Acquired Pneumonia.
Median enrollment 190 across the 42 interventional studies, 782 across the 9 observational. Of the 33 that completed or were terminated, 15 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 52 have an industry lead sponsor. The 10 most frequent:
Ann & Robert H Lurie Children's Hospital of Chicago is the lead sponsor of 178 studies on the registry; 25 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
Ann & Robert H Lurie Children's Hospital of Chicago has 3 studies filed under Community-Acquired Pneumonia — fewer than ten, so there is no comparison to draw.
2 of the studies in Community-Acquired Pneumonia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06669403Op-T LLCOPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis | 2027-03 |
| NCT06029933Kaiser PermanenteFluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Community-Acquired Pneumonia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are:
Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other.
Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.
This study is a multicenter, Hybrid Type-1effectiveness-implementation randomized clinical trial (RCT) designed to evaluate the effectiveness of a "Safety Net Antibiotic Prescribing" (SNAP) strategy versus an immediate antibiotic prescribing strategy for young children 12 months to \<6 years of age with community-acquired pneumonia (CAP) who are treated as outpatients.
This study will recruit eligible patients from approximately 19 clinical sites consisting of pediatric emergency departments (EDs), primary care offices, and urgent care centers within the United States and enroll up to 2,000 patients. Patient recruitment will occur over a 3.5-year period. Participants will be identified and screened during routine visits at the clinical sites.
Through an online system, participants will be randomized to either the immediate antibiotic group or the SNAP group. All participants will receive a prescription for antibiotics as per usual care from their treating clinician.
The parents or guardians of the participants will be asked to complete an online survey on Days 4 and 14 (+/- 2 days) to collect data for the secondary outcomes, including quality of life, satisfaction, and return visits. On Day 7 (+/- 2 days), the parents or guardians of the participants will be contacted by phone to collect data for the primary outcome, focusing on clinical improvement and antibiotic use.
Acceptability and feasibility will be assessed with parent or guardian and clinician surveys and interviews. Parents or guardians will be surveyed at Day 14 and a subset will be invited for interviews within a month of the final follow-up visit. Clinicians will be surveyed, and a subset will be interviewed at the conclusion of the trial.
The criteria were revised on the registry on Nov 17, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For participants randomized to this arm, a prescription is filled and the antibiotic is administered right after the index visit.
Other: Immediate Antibiotic Prescribing Group Instructions
For participants randomized to this arm, a prescription is provided, but the patient is instructed not to take the antibiotic unless the child is not improving at 72 hours or sooner if getting worse.
Other: Safety Net Antibiotic Prescribing (SNAP) Group Instructions
Children randomized to the immediate antibiotic prescribing group will receive an antibiotic prescription with instructions to fill and administer the antibiotics.
For children randomized to the SNAP group, their parents or guardians will receive a prescription for antibiotics, but will be told not to administer the antibiotic unless their child's symptoms show no improvement at 72 hours or worsen within 72 hours.
Clinical Improvement
Clinical improvement at 7 days after the index visit, defined as parent-reported (a) perception of overall improvement, (b) no worsening of fever, work of breathing, concerning changes in activity, or decreased oral intake, (c) no new antibiotic use or hospitalization following the index visit, and (d) improvement in at least one key pneumonia symptom in (b).
Time frame: From enrollment to day 7
Antibiotic Use
Antibiotic use through 7 days after the index visit, defined as Parent-reported antibiotic use (yes/no) at 7 days.
Time frame: From enrollment to day 7
Antibiotic Exposure
Antibiotic exposure, defined as the number of days antibiotics were consumed through day 7 and day 14.
Time frame: From enrollment to day 14
Clinical Improvement
Clinical improvement at day 4 and day 14. Clinical improvement is defined as parent-reported perception of overall improvement, no worsening of fever, work of breathing, concerning changes in activity, or decreased oral intake, no new antibiotic use or hospitalization following the index visit, and improvement in at least one of these key pneumonia symptoms. Symptom improvement is assessed on an ordinal scale with "Much Worse" as the minimum measurement and "Much Better" as the maximum measurement.
Time frame: From enrollment to day 14
Parent Satisfaction
Parent-reported satisfaction with the treatment strategy at day 14. Parent-reported satisfaction with the treatment strategy is assessed on an ordinal scale with "Very Dissatisfied" as the minimum measurement and "Very Satisfied" as the maximum measurement.
Time frame: From enrollment to day 14
Quality of Life Measures
Quality of life, defined by parent/guardian using the Pediatric Quality of Life Inventory (PedsQL) at days 7 and 14
Time frame: From enrollment to day 14
Return to Care
Parent-reported return to medical care after index visit and reason for return
Time frame: From enrollment to day 14
Antibiotic-associated Adverse Events
Rash, diarrhea, diaper dermatitis, oral thrush, vomiting, anaphylaxis
Time frame: From enrollment to day 14
Not enrolling at this site.
Plan to share: Yes — At the conclusion of the study, a de-identified dataset will be prepared and made available for sharing with investigators as specified by the lead investigators and the funding agency. Data sharing will follow established guidelines to ensure that any shared dataset does not contain protected health information (PHI) and is fully anonymized. Investigators requesting access to the dataset will need to submit a data use agreement, specifying how the data will be used. Results of the study will be disseminated through peer-reviewed journals, presentations at scientific meetings, and the PCORI website. Aim 3 interview transcripts will not be shared to a publicly available repository since it will be impossible to fully anonymize the transcripts.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Jun 2029, 45 months after the start.
Of 42 non-industry interventional studies with no phase under Community-Acquired Pneumonia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 38. This study's planned 45 months is above that.
Counting every sponsor, half of 43 studies reached it within 24 months; a quarter within 14 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Community-Acquired Pneumonia →
Ann & Robert H Lurie Children's Hospital of Chicago →